These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1002 related articles for article (PubMed ID: 25923550)

  • 1. Rociletinib in EGFR-mutated non-small-cell lung cancer.
    Sequist LV; Soria JC; Goldman JW; Wakelee HA; Gadgeel SM; Varga A; Papadimitrakopoulou V; Solomon BJ; Oxnard GR; Dziadziuszko R; Aisner DL; Doebele RC; Galasso C; Garon EB; Heist RS; Logan J; Neal JW; Mendenhall MA; Nichols S; Piotrowska Z; Wozniak AJ; Raponi M; Karlovich CA; Jaw-Tsai S; Isaacson J; Despain D; Matheny SL; Rolfe L; Allen AR; Camidge DR
    N Engl J Med; 2015 Apr; 372(18):1700-9. PubMed ID: 25923550
    [TBL] [Abstract][Full Text] [Related]  

  • 2. AZD9291 in EGFR inhibitor-resistant non-small-cell lung cancer.
    Jänne PA; Yang JC; Kim DW; Planchard D; Ohe Y; Ramalingam SS; Ahn MJ; Kim SW; Su WC; Horn L; Haggstrom D; Felip E; Kim JH; Frewer P; Cantarini M; Brown KH; Dickinson PA; Ghiorghiu S; Ranson M
    N Engl J Med; 2015 Apr; 372(18):1689-99. PubMed ID: 25923549
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety, tolerability, and anti-tumor activity of olmutinib in non-small cell lung cancer with T790M mutation: A single arm, open label, phase 1/2 trial.
    Kim DW; Lee DH; Han JY; Lee J; Cho BC; Kang JH; Lee KH; Cho EK; Kim JS; Min YJ; Cho JY; An HJ; Kim HG; Lee KH; Kim BS; Jang IJ; Yoon S; Han O; Noh YS; Hong KY; Park K
    Lung Cancer; 2019 Sep; 135():66-72. PubMed ID: 31447004
    [TBL] [Abstract][Full Text] [Related]  

  • 4. First-in-Human Phase I Study of AC0010, a Mutant-Selective EGFR Inhibitor in Non-Small Cell Lung Cancer: Safety, Efficacy, and Potential Mechanism of Resistance.
    Ma Y; Zheng X; Zhao H; Fang W; Zhang Y; Ge J; Wang L; Wang W; Jiang J; Chuai S; Zhang Z; Xu W; Xu X; Hu P; Zhang L
    J Thorac Oncol; 2018 Jul; 13(7):968-977. PubMed ID: 29626621
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Osimertinib for Japanese patients with T790M-positive advanced non-small-cell lung cancer: A pooled subgroup analysis.
    Hirashima T; Satouchi M; Hida T; Nishio M; Kato T; Sakai H; Imamura F; Kiura K; Okamoto I; Kasahara K; Uchida H; Vowler SL; Mitsudomi T
    Cancer Sci; 2019 Sep; 110(9):2884-2893. PubMed ID: 31265163
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase II Efficacy and Safety of 80 mg Osimertinib in Patients With Leptomeningeal Metastases Associated With Epidermal Growth Factor Receptor Mutation-Positive Non-Small Cell Lung Cancer (BLOSSOM).
    Park S; Baldry R; Jung HA; Sun JM; Lee SH; Ahn JS; Kim YJ; Lee Y; Kim DW; Kim SW; Lee KH; Lee WJ; Choi JW; Chong K; Lee JI; Gwon SH; Son NH; Ahn MJ
    J Clin Oncol; 2024 Aug; 42(23):2747-2756. PubMed ID: 38828959
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Discovery of a mutant-selective covalent inhibitor of EGFR that overcomes T790M-mediated resistance in NSCLC.
    Walter AO; Sjin RT; Haringsma HJ; Ohashi K; Sun J; Lee K; Dubrovskiy A; Labenski M; Zhu Z; Wang Z; Sheets M; St Martin T; Karp R; van Kalken D; Chaturvedi P; Niu D; Nacht M; Petter RC; Westlin W; Lin K; Jaw-Tsai S; Raponi M; Van Dyke T; Etter J; Weaver Z; Pao W; Singh J; Simmons AD; Harding TC; Allen A
    Cancer Discov; 2013 Dec; 3(12):1404-15. PubMed ID: 24065731
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A phase I study of FCN-411, a pan-HER inhibitor, in EGFR-mutated advanced NSCLC after progression on EGFR tyrosine kinase inhibitors.
    Lin L; Pan H; Li X; Zhao C; Sun J; Hu X; Zhang Y; Wang M; Ren X; Luo X; Shan G; Hui AM; Wu Z; Liu H; Tian L; Shi Y
    Lung Cancer; 2022 Apr; 166():98-106. PubMed ID: 35248866
    [TBL] [Abstract][Full Text] [Related]  

  • 9. First-in-human phase I study of BEBT-109 in previously treated EGFR exon 20 insertion-mutated advanced non-small cell lung cancer.
    Zeng L; Song L; Liu L; Wu F; Xu Q; Yan H; Lin S; Jiang W; Wang Z; Deng L; Qin H; Zhang X; Xiao J; Liu M; Liu Z; Zhang L; Zhou C; Xiong Y; Wang Y; Zhang Y; Yang N
    Med; 2024 May; 5(5):445-458.e3. PubMed ID: 38521070
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [3rd generation's TKI in lung cancer non-small cell EGFR-mutated having acquired a secondary T790M resistance].
    Brosseau S; Viala M; Varga A; Planchard D; Besse B; Soria JC
    Bull Cancer; 2015 Sep; 102(9):749-57. PubMed ID: 26235419
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety, efficacy, and pharmacokinetics of SH-1028 in EGFR T790M-positive advanced non-small cell lung cancer patients: A dose-escalation phase 1 study.
    He J; Ma P; Zhao D; Shi X; Guo R; Gao W; Shu Y
    Cancer; 2023 May; 129(10):1513-1522. PubMed ID: 36813747
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Heterogeneity Underlies the Emergence of EGFRT790 Wild-Type Clones Following Treatment of T790M-Positive Cancers with a Third-Generation EGFR Inhibitor.
    Piotrowska Z; Niederst MJ; Karlovich CA; Wakelee HA; Neal JW; Mino-Kenudson M; Fulton L; Hata AN; Lockerman EL; Kalsy A; Digumarthy S; Muzikansky A; Raponi M; Garcia AR; Mulvey HE; Parks MK; DiCecca RH; Dias-Santagata D; Iafrate AJ; Shaw AT; Allen AR; Engelman JA; Sequist LV
    Cancer Discov; 2015 Jul; 5(7):713-22. PubMed ID: 25934077
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase I study of TAS-121, a third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, in patients with non-small-cell lung cancer harboring EGFR mutations.
    Nishio M; Murakami H; Ohe Y; Hida T; Sakai H; Kasahara K; Imamura F; Baba T; Kubota K; Hosomi Y; Shimokawa T; Hayashi H; Miyadera K; Tamura T
    Invest New Drugs; 2019 Dec; 37(6):1207-1217. PubMed ID: 30790152
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Assessment of EGFR Mutation Status in Matched Plasma and Tumor Tissue of NSCLC Patients from a Phase I Study of Rociletinib (CO-1686).
    Karlovich C; Goldman JW; Sun JM; Mann E; Sequist LV; Konopa K; Wen W; Angenendt P; Horn L; Spigel D; Soria JC; Solomon B; Camidge DR; Gadgeel S; Paweletz C; Wu L; Chien S; O'Donnell P; Matheny S; Despain D; Rolfe L; Raponi M; Allen AR; Park K; Wakelee H
    Clin Cancer Res; 2016 May; 22(10):2386-95. PubMed ID: 26747242
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy, safety, and genetic analysis of furmonertinib (AST2818) in patients with EGFR T790M mutated non-small-cell lung cancer: a phase 2b, multicentre, single-arm, open-label study.
    Shi Y; Hu X; Zhang S; Lv D; Wu L; Yu Q; Zhang Y; Liu L; Wang X; Cheng Y; Ma Z; Niu H; Wang D; Feng J; Huang C; Liu C; Zhao H; Li J; Zhang X; Jiang Y; Gu C
    Lancet Respir Med; 2021 Aug; 9(8):829-839. PubMed ID: 33780662
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Analysis of resistance mechanisms to abivertinib, a third-generation EGFR tyrosine kinase inhibitor, in patients with EGFR T790M-positive non-small cell lung cancer from a phase I trial.
    Zhang YC; Chen ZH; Zhang XC; Xu CR; Yan HH; Xie Z; Chuai SK; Ye JY; Han-Zhang H; Zhang Z; Bai XY; Su J; Gan B; Yang JJ; Li WF; Tang W; Luo FR; Xu X; Wu YL; Zhou Q
    EBioMedicine; 2019 May; 43():180-187. PubMed ID: 31027916
    [TBL] [Abstract][Full Text] [Related]  

  • 17. AC0010, an Irreversible EGFR Inhibitor Selectively Targeting Mutated EGFR and Overcoming T790M-Induced Resistance in Animal Models and Lung Cancer Patients.
    Xu X; Mao L; Xu W; Tang W; Zhang X; Xi B; Xu R; Fang X; Liu J; Fang C; Zhao L; Wang X; Jiang J; Hu P; Zhao H; Zhang L
    Mol Cancer Ther; 2016 Nov; 15(11):2586-2597. PubMed ID: 27573423
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rociletinib, a third generation EGFR tyrosine kinase inhibitor: current data and future directions.
    Chuang JC; Salahudeen AA; Wakelee HA
    Expert Opin Pharmacother; 2016; 17(7):989-93. PubMed ID: 26950414
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Third-generation inhibitors targeting EGFR T790M mutation in advanced non-small cell lung cancer.
    Wang S; Cang S; Liu D
    J Hematol Oncol; 2016 Apr; 9():34. PubMed ID: 27071706
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rociletinib in EGFR-Mutated Non-Small-Cell Lung Cancer.
    Sequist LV; Rolfe L; Allen AR
    N Engl J Med; 2015 Aug; 373(6):578-9. PubMed ID: 26244318
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 51.